National Tsing Hua University (NTHU) in Taiwan signed a BOT hospital contract with privately owned Kaohsiung Medical University (KMU) on July 4th, with NTHU President W. John Kao (高為元) and…
Braven, an early stage investment firm focused on regulated ecosystems, today announced the launch of its new Healthcare & Life Sciences Unit, focusing on next-gen platforms merging machine intelligence and…
The At-Home in vitro diagnostic (IVD) testing market is comprised of IVD tests that can be purchased at the local store or on the Internet where the patient gathers the…
Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC) at…
Ribbon Biolabs, the DNA synthesis company, today announced the appointment of Roopom Banerjee as Executive Chairman of its Board of Directors. He brings 25 years of strategy, operations, business development,…
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (CNS) disorders, today provided a corporate…
CANbridge Pharmaceuticals, Inc. (1228.HK), a global biopharmaceutical company, with a foundation in China, committed to the research, development and commercialization of transformative therapies to treat rare diseases and oncology, announced positive…
Takeda (TSE: 4502/NYSE:TAK) today presented favorable interim results from a global pivotal Phase 3 randomized, controlled, open-label, crossover trial evaluating the safety and efficacy of TAK-755 (recombinant ADAMTS13) replacement therapy…
A clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported data from the Phase 1b proof-of-concept study…
At the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 annual meeting, GE HealthCare (Nasdaq: GEHC) is proud to showcase new, innovative technologies and diagnostics that enable personalized medicine…
Arrowhead Pharmaceuticals today presented updated results from the Phase 2 SEQUOIA clinical study of investigational fazirsiran (TAK-999/ARO-AAT) for the treatment of liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). The…
Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase…